ElpasBio Completes Patient Enrollment in Phase III Pivotal Clinical Trial of AlloJoin®

AlloJoin® is one of the few stem cell product candidates in late-stage clinical development worldwide ElpasBio is planning for data readout and NDA by next year ElpasBio partnered with Fosun Kairos to accelerate AlloJoin® commercialization in China SHANGHAI, June 3, 2026 /PRNewswire/ --...